Cassava Sciences | PTIE - Current Assets


Cassava Sciences reported $80.06M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Abbott USD 23.5B 1.02B Sep/2026
Amgen USD 34.36B 598M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Cassava Sciences USD 80.06M 3.67M Sep/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 65.26B 591M Sep/2026
Geron USD 468.74M 17.6M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Novavax USD 707.96M 63.14M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026